1. EGFR Mutations in Lung Cancer: Correlation with ClinicalResponse to Gefitinib Therapy.
- Author
-
Paez, J. Guillermo, Janne, Pasi A., Lee, Jeffrey C., Tracy, Sean, Greulich, Heidi, Gabriel, Stacey, Herman, Paula, Kaye, Frederic J., Lindeman, Neal, Boggon, Titus J., Naoki, Katsuhiko, Sasaki, Hidefumi, Fujii, Yoshitaka, Eck, Michael J., Sellers, William R., Johnson, Bruce E., and Meyerson, Matthew
- Subjects
- *
PROTEIN-tyrosine kinases , *SMALL cell lung cancer , *GENETIC mutation , *TUMORS , *CELL lines - Abstract
Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene ECFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gef itinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. ECFR mutations were found in additional lung cancer samples from D.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that ECFR mutations may predict sensitivity to gefitinib. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF